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Abstract
Background:  Since visceral fat tissue is known to release various inflammatory and anti-
inflammatory cytokines, abdominal obesity may play a key role in the inflammation associated with
metabolic syndrome (MetS). However, few studies have determined precise relationships of
abdominal obesity with inflammatory markers in MetS. To clarify the importance of abdominal
obesity in sub-clinical inflammation, we examined the changes of inflammatory markers in clustering
of MetS components with or without abdominal obesity.
Methods: Subjects consisted of 326 apparently healthy Japanese men (age: 30 to 59 years) who
underwent health examination in the Osaka University Health Care Center. MetS components
were assessed and serum levels of high sensitive C-reactive protein (hs-CRP), interleukin (IL)-6 and
adiponectin were examined in all subjects.
Results: Subjects with abdominal obesity (waist circumference ≥ 85 cm) showed higher serum hs-
CRP and IL-6 levels and a lower adiponectin level than those without abdominal obesity. Serum
levels of hs-CRP and IL-6 significantly increased in association with clustering of MetS components
in the subjects with abdominal obesity, but not in those without abdominal obesity. On the other
hand, serum adiponectin level exhibited a little change with clustering of MetS components in the
subjects with abdominal obesity. Significant negative correlation between adiponectin and hs-CRP
was observed in the subjects with abdominal obesity, however this correlation was not detected
in obese subjects defined by body mass index ≥ 25.
Conclusion: Inflammatory status is not exaggerated by clustering of MetS components in the
subjects without abdominal obesity. Abdominal obesity may exhibit distinct effect on inflammatory
and anti-inflammatory proteins and modulate inflammatory network in MetS.
Background
National Cholesterol Education Program (NCEP)-Adult
Treatment Panel (ATP) III, and American Heart Associa-
tion (AHA)/National Heart Lung and Blood Institute
(NHLBI) proposed definitions of the metabolic syndrome
(MetS) as a cluster of at least 3 of 5 following risk factors,
abdominal obesity, raised blood pressure, hyper-triglycer-
idemia, hypo-HDL-cholesterolemia, and raised fasting
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blood glucose [1,2]. The primary mechanism for cluster-
ing of metabolic abnormalities has yet to be elucidated,
but insulin resistance or accumulation of visceral fat is
believed as an encouraging candidate [3,4]. As for visceral
fat, the International Diabetes Federation (IDF) newly rec-
ommended a definition in which abdominal obesity is
the essential component of MetS [5,6].
Recent studies have proposed an association between
MetS and inflammatory markers [7-10]. Abdominal obes-
ity, especially a visceral fat, may play a key role in these sit-
uations, because adipose tissue is known to secrete many
bioactive substances, including inflammatory and anti-
inflammatory proteins [11,12]. However, only few studies
have precisely examined the significance of abdominal
obesity in the inflammatory changes observed in MetS
[13,14].
In the present study, we examined inflammatory and anti-
inflammatory proteins in Japanese middle-aged men, and
investigated whether presence of abdominal obesity has
an impact on the inflammatory responses. We here
describe unique associations among abdominal obesity,
clustering of MetS components, and inflammatory and
anti-inflammatory markers.
Methods
Study population
A total of 326 apparently healthy Japanese men, 30 to 59
years of age, who underwent health examination in the
Osaka University Health Care Center, were evaluated with
MetS components. Individuals with a history of acute ill-
ness within 2 weeks or who had taken any medicine were
excluded (n = 31) in order to avoid effects on serum levels
of inflammatory proteins. Same numbers of subjects with
or without abdominal obesity were consecutively
selected. Comparison was performed between an
"abdominal obesity group" who met the criterion of waist
circumference for abdominal obesity and a "non-abdom-
inal obesity group" who did not meet this criterion.
Informed consent was obtained from all subjects prior to
participation in the study following approval of the study
by the Ethics Committee of Osaka University.
Risk factor assessment
Waist circumference at the umbilical level was measured
in the late exhalation phase in standing position. Abdom-
inal obesity was diagnosed by waist circumference ≥ 85
cm using the guidelines for abdominal obesity in Japanese
individuals [15]. To examine the significant role of
abdominal obesity, we employed the definition by IDF
[5]. In the criteria of IDF, abdominal obesity is a prerequi-
site risk factor, and MetS was defined by the existence of
abdominal obesity and at least 2 of 4 MetS components
defined as follows: 1)    hypertriglyceridemia: a serum
level of triglycerides (TG) ≥150 mg/dl; 2) low HDL choles-
terolemia: a serum level of HDL cholesterol (HDL-C) < 40
mg/dl; 3) hypertension: systolic blood pressure (SBP) ≥
130 mmHg, or diastolic blood pressure (DBP) ≥ 85
mmHg; 4) high fasting glucose: plasma level of glucose
(FPG) ≥100 mg/dl.
Laboratory measurements
Serum was collected from subjects after an overnight fast
and kept at ≤ -20°C until assay. Serum immunoreactive
insulin was measured by a standard radioimmunoassay
method (Dinabott Co., Tokyo, Japan). Homeostasis
model assessment of insulin resistance (HOMA-IR) was
defined as the product of fasting plasma insulin (µU/ml)
and glucose (mg/dl) divided by 405 [16]. Low density
lipoprotein cholesterol (LDL-C) was calculated by the
Friedewald formula. However, LDL-C was not calculated
if the TG level was >300 mg/dl. Serum high sensitive-C
reactive protein (hs-CRP) level was measured with an
immunoenzymeassay (Dase Behring, Marburg, Ger-
many). Serum interleukin (IL)-6 concentration was meas-
ured in duplicate with a chemiluminescent enzyme
immunoassay (CLEIA) (Fujirebio Inc., Tokyo, Japan), and
adiponectin was measured duplicate by a sandwich
enzyme-linked immunosorbent assay (ELISA) system by
adiponectin ELISA kit (Otsuka Pharmaceutical Co.,
Tokushima, Japan) [17,18].
Before conducting present study, interclass CVs of hs-CRP,
IL-6, and adiponectin measurements were examined (n =
40). Mean CVs of hs-CRP, IL-6, and adiponectin measure-
ments in our assays were 1.1%, 4.5%, and 1.2%, respec-
tively. The same lots of these kits were used in the study to
keep reliability of the measurements.
Statistical analysis
All values are mean ± SD. Pearson's correlation coeffi-
cients were calculated among skewed variables after loga-
rithmic transformation of variables. ANOVA with
Bonferroni post hoc test was used to assess difference
between groups. Values of P < 0.05 were considered statis-
tically significant.
Results
Profiles of the study subjects are shown in Table 1. Tradi-
tional risk factors were exacerbated and HOMA-IR was
increased in abdominal obesity group as compared with
non-abdominal obesity group. Abdominal obesity group
presented significantly higher hs-CRP and IL-6 levels, and
a lower adiponectin level than non-abdominal obesity
group.
The effects of clustering MetS components on inflamma-
tory status were compared between these two groups.
Interestingly, in non-abdominal obesity group, serum lev-Cardiovascular Diabetology 2007, 6:27 http://www.cardiab.com/content/6/1/27
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els of hs-CRP and IL-6 changed a little in association with
clustering of MetS components (Figure 1A). However,
serum levels of hs-CRP and IL-6 significantly increased in
association with clustering of MetS components in
abdominal obesity group (Figure 1B). On the other hand,
serum adiponectin level exhibited a little change with
clustering of MetS components in abdominal obesity
group (Figure 1B), while it was significantly decreased in
non-abdominal obesity group. These findings suggest that
abdominal obesity may be a key factor in modulating the
inflammatory reactions observed in MetS.
We next examined whether these changes of inflamma-
tory markers associate with traditional risk factors. The
mean value of risk factor in the subjects either with low or
high level of inflammatory marker was compared. Signif-
icance of difference was summarized in Table 2. The mean
values of waist, TG, and HDL-C showed significant
changes associated with classification of adiponectin and
hs-CRP levels. FPG was significantly changed between
subjects with high and low adiponectin levels. SBP, and
DBP levels were significantly changed between subjects
with high and low hs-CRP levels. Moreover, stepwise
regression analysis revealed waist circumference was a sig-
nificant determinant for the levels of adiponectin, IL-6,
and hs-CRP (Standard regression co-efficient: -0.237,
0.115, and 0.256; F value: 18.6, 4.1, and 20.9; respec-
tively)
Networks of inflammatory and anti-inflammatory pro-
teins may be altered by the presence of abdominal obes-
ity. Therefore, we next examined the correlation of these
markers both in the subjects with abdominal obesity and
in obese subjects defined by body mass index (BMI) ≥ 25.
As shown in Table 3, correlation was not observed
between serum adiponectin and hs-CRP levels in obese
subjects (BMI ≥ 25), and even in those with two or more
MetS components. However, there was a significant nega-
tive correlation between serum adiponectin and hs-CRP
levels in abdominal obesity group (r = -0.23 [95%CI, -
0.37 to -0.08]). In addition, significant correlation was
detected in the subjects with abdominal obesity with two
or more MetS components, i.e. MetS (r = -0.29 [95%CI, -
0.53 to -0.01]). No significant correlation was observed
between adiponectin and IL-6 in both obese and abdom-
inal obese subjects (data not shown).
Discussion
It is considered that clustering of metabolic abnormalities
presents synergistic effects on cardiovascular complica-
tions beyond the sum of effects of individual abnormali-
Serum levels of hs-CRP, IL-6, and adiponectin Figure 1
Serum levels of hs-CRP, IL-6, and adiponectin. A. 
Serum levels of hs-CRP, IL-6, and adiponectin in non-abdom-
inal obesity group. Open, hatched, and closed columns rep-
resent the subjects with no, one, and two or more metabolic 
syndrome components except for waist criteria, respectively. 
Numbers of subjects in open, hatched, and closed columns 
were 95, 50, and 18, respectively. B. Serum levels of hs-CRP, 
IL-6, and adiponectin in abdominal obesity group. Columns 
represent same as described in A. Numbers of subjects in 
open, hatched, and closed columns were 57, 57, and 49, 
respectively. Data are mean ± SD. *p < 0.05, **p < 0.01 vs. 
no metabolic syndrome component (open columns). hs-CRP: 
high sensitive C-reactive protein; IL-6: interleukin-6; MetS: 
metabolic syndrome.
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Table 1: Characteristics of the study subjects
All Subjects Non-abdominal 
obesity group
Abdominal 
obesity group
P
n 326 163 163
Age, y 45.1 ± 8.1 45.3 ± 8.4 44.8 ± 7.7 n.s.
Waist, cm 84.8 ± 8.2 78.3 ± 4.7 91.2 ± 5.2 <0.0001
BMI, kg/m2 24.3 ± 3.3 22.1 ± 2.0 26.6 ± 2.8 <0.0001
SBP, mmHg 123 ± 16 120 ± 14 127 ± 17 <0.0001
DBP, mmHg 79 ± 12 76 ± 11 82 ± 13 <0.0001
TC, mg/dl 208 ± 35 203 ± 33 214 ± 37 0.003
TG, mg/dl 131 ± 128 100 ± 53 162 ± 168 <0.0001
HDL-C, mg/dl 58 ± 14 62 ± 15 53 ± 11 <0.0001
LDL-C, mg/dl 125 ± 34 120 ± 31 129 ± 37 0.03
FPG, mg/dl 91 ± 10 89 ± 9 93 ± 10 0.0009
HOMA-IR 1.35 ± 2.03 0.75 ± 0.29 1.87 ± 2.67 0.03
hs-CRP, mg/L 0.68 ± 0.77 0.58 ± 0.82 0.78 ± 0.71 0.018
IL-6, pg/ml 1.26 ± 0.75 1.18 ± 0.66 1.34 ± 0.83 0.045
Adiponectin, µg/ml 6.3 ± 2.9 7.1 ± 3.3 5.5 ± 2.1 < 0.0001
Data are mean ± SD. Abdominal obesity and non-abdominal obesity groups are the 
subjects who met or did not meet the waist criteria (≥ 85 cm). BMI: body mass 
index; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total 
cholesterol; TG: triglycerides; HDL-C: HDL cholesterol; LDL-C: LDL cholesterol; 
FPG: fasting plasma glucose; HOMA-IR: homeostasis model assessment of insulin 
resistance; hs-CRP: high sensitive C reactive protein; IL-6: interleukin-6. Statistical 
significance was examined between non-abdominal obesity and abdominal obesity 
groups.Cardiovascular Diabetology 2007, 6:27 http://www.cardiab.com/content/6/1/27
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ties [19]. Therefore, to elucidate the mechanism in
clustering of metabolic abnormalities is an important
issue. In the present study, percentage of the subjects with
two or more MetS components was markedly higher in
the abdominal obesity group (30.1%) than the non-
abdominal obesity group (11.0%) (data not shown).
Abdominal obesity, therefore, might play a pivotal role
among various MetS components in the practical defini-
tion of MetS. When abdominal obesity was absent,
inflammatory proteins, such as hs-CRP and IL-6, did not
increase significantly with clustering of MetS components
(Figure 1A), despite the fact that previous studies found
an association between CRP and MetS [7,20]. Our results
clearly demonstrated association between hs-CRP/IL-6
levels and clustering of MetS components predominantly
in the presence of abdominal obesity. Although BMI
might also alter inflammatory status, classification by BMI
did not present clear association between inflammation
and clustering of MetS components (data not shown).
Inflammation may be an important underlying etiology
of MetS [8] through its various effects mediated by adi-
pose tissue-derived factors, such as leptin, adiponectin, IL-
6, IL-10 and etc. [12]. Many studies demonstrated associ-
ations between inflammatory proteins and MetS, abdom-
inal obesity, or insulin resistance. Our results also
demonstrate the importance of waist circumference in the
changes of inflammatory markers (Table 2). However,
abdominal obesity has usually been evaluated as one of
the components of MetS. In the present study, we clearly
showed that abdominal obesity exhibits distinct associa-
tion with inflammatory and anti-inflammatory proteins
in clustering of MetS components in apparently healthy
subjects.
Adiponectin, an anti-inflammatory protein [21], has been
demonstrated to be insulin-sensitizing and anti-athero-
genic factor, and is considered a key component of MetS
[11,22,23]. Serum adiponectin level was significantly
lower in the subjects with abdominal obesity than those
without it, and a marked decrease was observed with clus-
tering of MetS components only in the subjects without
abdominal obesity. In agreement with previous reports,
low level of serum adiponectin is a potent risk for MetS,
and elevation of serum hs-CRP and IL-6 concentration
enhances the incidence of MetS in the subjects with
abdominal obesity.
Previously, an inverse correlation between expression lev-
els of CRP and adiponectin in adipose tissue from the
patients with coronary artery disease had been demon-
strated [24]. In the present study, a significant negative
correlation was observed between serum adiponectin and
hs-CRP levels in the subjects with abdominal obesity, but
not in obese subjects. These results suggest that abdomi-
nal obesity may exhibit distinct effect on inflammatory
and anti-inflammatory proteins. Recently, it is reported
that portal concentration of IL-6 is higher than peripheral
concentration of it, and visceral fat is identified as an
important site for IL-6 secretion [25]. Thus, portal IL-6
from visceral fat might directly induce the production of
CRP in the liver. In addition, macrophages infiltrating
into visceral fat is another possibility for inflammatory
networks specific to the abdominal obesity. It has been
reported that macrophage is a source of adipose tissue-
derived proteins [26]. The increased number of macro-
phages infiltrating the visceral fat tissue in individuals
with abdominal obesity suggests that adipose tissue itself
is a source and site of inflammation [27]. Thus, the
inflammatory networks associated with abdominal obes-
ity were distinct from those associated with mere "obes-
ity". Després and Lemienx proposed visceral fat as a
dysfunctional adipose tissue [4], and our results support
this idea.
In conclusion, without abdominal obesity, inflammatory
status is not exaggerated by clustering of MetS compo-
nents in apparently healthy middle-aged men. Abdomi-
nal obesity may exhibit distinct effect on inflammatory
Table 3: Correlation between serum adiponectin and hs-CRP 
levels in obesity and abdominal obesity groups
Group n Correlation 
coefficients
95% CI P
Obesity (BMI ≥ 25)  129 -0.05 -0.22 to 0.13 0.61
with ≥ 2 MetS components 42 -0.12 -0.41 to 0.19 0.44
Abdominal obesity (Waist ≥ 85)  163 -0.23 -0.37 to -0.08 0.003
with ≥ 2 MetS components 49 -0.29 -0.53 to -0.01 0.045
Obesity group includes the subjects with body mass index (BMI) ≥ 25. Abdominal 
obesity group includes the subjects with waist circumference ≥ 85 cm. MetS: 
metabolic syndrome. Significant negative correlation between adiponectin and hs-
CRP was detected only in the abdominal obesity group. Bold values indicate p < 
0.05.
Table 2: Difference in mean values of risk factors between the 
subjects with "High" and "Low" inflammatory markers
"High" and "Low" Groups
Adiponectin IL-6 hs-CRP
Waist <0.0001 0.18 <0.0001
SBP 0.66 0.069 0.0003
DBP 0.21 0.40 0.002
LDL-C 0.82 0.21 0.20
TG 0.0031 0.10 0.0078
HDL-C <0.0001 0.098 <0.0001
FPG 0.019 0.91 0.46
HbA1c 0.19 0.62 0.50
HOMA-IR 0.11 0.30 0.076
Groups of "High" and "Low" inflammatory markers were divided by 
the half number of the subjects. Abbreviations are same as described 
in Table 1. Bold values indicate p < 0.05.Cardiovascular Diabetology 2007, 6:27 http://www.cardiab.com/content/6/1/27
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and anti-inflammatory proteins and modulates inflam-
matory network in MetS.
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